The symposium should be an important resource for clinicians and stimulate further study of the pathogenesis and treatment of these diseases.

 

Gestational trophoblastic disease in ectopic pregnancy is a rare condition and usually produces tubal rupture.

Persistent gestational trophoblastic neoplasia requiring chemotherapy occasionally occurs after partial hydatidiform mole, and surveillance of all cases continues to be recommended.

Intensive multimodality therapy for high-risk GTN using EMA-CO or some variation of it, along with adjuvant radiotherapy and surgery, results in primary remission rates of 65-80%.

Adjuvant surgical procedures, especially hysterectomy and pulmonary resection for chemotherapy-resistant disease as well as procedures to control hemorrhage, are important components in the management of high-risk gestational trophoblastic neoplasia.

This study summarized trends by race and ethnicity in gestational trophoblastic disease and choriocarcinoma using New Mexico and Surveillance, Epidemiology and End Results registry data.

Intracranial metastasis in GTN is a curable disease that carries compromised survival because of difficulty in implementing the treatment regimen, patient noncompliance and late diagnosis.

Until standards for hyperglycosylated hCG and hCG minus the bCTP are available, automated and manual tests cannot be developed that correct the specificity problems.

In cases of low serum hCG levels, it is impossible to overstate the importance of distinguishing nonmalignant states from malignancy using readily available biochemical tests before starting therapy.

Although postpartum choriocarcinoma is extremely uncommon, there is a need for physicians in all disciplines to remain aware of this possibility in patients with persistent postpartum vaginal bleeding.

The syndrome is often diagnosed late, is associated with a reduced live birth rate and is at increased risk of complications, such as preeclampsia and hemorrhage.

Failure of treatment in relapsed gestational trophoblastic neoplasia seems attributable to patients who defaulted treatment or follow-up and presented late with massive disease.

Clinical examinations and serum b-hCG assays are the keys to diagnosing postmolar GTD at the earliest time so that single-agent chemotherapy with a minimum number of courses can achieve complete remission.

Our educational and publication activity made it possible for us to treat 80% of trophoblastic tumor patients from the 10.5 million population of Hungary.

It ought to be the objective of this society to ensure that all patients, anywhere in the world, who suffer any form of trophoblastic disease, from hydatidiform mole onwards, receive the benefit of expert management.